Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

MDS with Isolated Neutropenia or Thrombocytopenia. Incidence and Characteristics in the Groupe Francophone des Myélodysplasies (GFM) Registry.

Sophie Park, MD, V. Andrieu, R. Sapena, G. Leroux, A. Stamatoullas, M.P. Callat, O. Beyne-Rauzy, J. Mairesse, M.P. Chaury, Herve Dombret, V. Siguret, Norbert Vey, G. Lepeu, A. Guerci, S. Cheze, Pierre Fenaux, F. Dreyfus

Blood (2007) 110 (11): 2456.

https://doi.org/10.1182/blood.V110.11.2456.2456

Published: 2007

Journal Articles

Bortezomib + Low Dose Cytarabine in Int-2 and High Risk MDS. Interim Results of a Phase I/II Trial by the GFM.

Shanti Natarajan, Pierre Fenaux, Norbert Vey, A. Guerci, I. Coulibaly, A. Charbonnier, C. Ravoet, S. Courby, G. Etienne, M.P. Chaury, S. Cheze, A. Stamatoullas, L. Legros, E. Berger, A. Lescoute, S. Vaultier, F. Dreyfus

Blood (2007) 110 (11): 1453.

https://doi.org/10.1182/blood.V110.11.1453.1453

Published: 2007

Journal Articles

Lenalidomide (LEN) in INT 2 and High Risk MDS with DEL 5q. Interim Results of a Phase II Trial by the GFM.

S. Burcheri, MD, T. Prebet, MD, O. Beyne-Rauzy, MD, R.M. Mbida, MD, N. Hoarau, MD, L. Legros, MD, C. Ravoet, MD, F. Dreyfus, MD, A. Stamatoullas, MD, M.P. Chaury, MD, J. Delaunay, MD, G. Laurent, MD, N. Vey, MD, L. Ades, MD, C. Gardin, MD, Pierre Fenaux, MD

Blood (2007) 110 (11): 820.

https://doi.org/10.1182/blood.V110.11.820.820

Published: 2007

Journal Articles

Prognostic Factors and Response Duration in 419 MDS Treated with Erythropoietin±GCSF: The GFM Experience.

Blood (2006) 108 (11): 522.

https://doi.org/10.1182/blood.V108.11.522.522

Published: 2006

Journal Articles

RBC Transfusions and Iron Chelation Therapy in Clinical Practice in MDS: A One Month Survey by the GFM.

Christian Rose, MD, A. Stamatoulas, MD, D. Vassilief, MD, S. Brechignac, MD, O. Beyne-Rauzy, MD, F. Courtois, MD, M. Wemeau, MD, Agnes Guerci, MD, M.P. Chaury, MD, B. Lefs, MD, B. Mahe, MD, L. Roy, MD, Bruno Quesnel, PD, MD, F. Dreyfus, PD, MD, Pierre Fenaux, PD, MD

Blood (2006) 108 (11): 2661.

https://doi.org/10.1182/blood.V108.11.2661.2661

Published: 2006

Journal Articles

Low Doses of Thalidomide (Thal) in Low Risk MDS with Transfusion-Dependant Anemia: The GFM THAL-SMD-200 Trial.

J. Tamburini, C. Elie, D. Vassilief, M.C. Quarre, O. Beyne-Rauzy, M. Gardembas, A. Aouba, C. Berthou, L. Sanhes, A. Guerci, A. Stamatoullas, F. Bauduer, J.J. Sotto, L. Legros, S. Vaultier, P. Fenaux, F. Dreyfus, D. Bouscary

Blood (2006) 108 (11): 2673.

https://doi.org/10.1182/blood.V108.11.2673.2673

Published: 2006

Journal Articles

Is There a Role for ATRA in Combination to EPO in Lower Risk Myelodysplastic Syndrome? Preliminary Results of a Phase II Study.

Blood (2005) 106 (11): 2537.

https://doi.org/10.1182/blood.V106.11.2537.2537

Published: 2005

Journal Articles

Thalidomide for the Treatment of Low Risk Myelodysplasia.

D. Bouscary, MD-PhD, M. C. Quarre, MD, D. Vassilief, MD, O. Beyne Rouzy, MD, A. Aouba, MD, C. Berthou, MD, C. Gardembas, MD, L. Sanhes, MD, A. Guerci, MD, B. Mahe, MD, A. Stamatoullas, MD, F. Bauduer, MD, J. J. Sotto, MD, L. Legros, MD-PhD, S. Vaultier, ARC, P. Fenaux, MD-PhD, F. Dreyfus, MD

Blood (2004) 104 (11): 1438.

https://doi.org/10.1182/blood.V104.11.1438.1438

Published: 2004

Journal Articles

High Response Rate to Darbopoetin Alfa in “Low Risk” MDS : Results of a Phase II Study.

L. Mannone, C. Gardin, M.C. Quarre, J.F. Bernard, S. Giraudier, E. Rosenthal, D. Vassilief, F. Hamza, S. Park, J.J. Kiladjian, S. Vaultier, Mo Beyne-Rouzy, S. Cheze, L. Voilliat, P. Agape, F. Dreyfus, P. Fenaux

Blood (2004) 104 (11): 69.

https://doi.org/10.1182/blood.V104.11.69.69

Published: 2004

Journal Articles

Blockade of p110delta Isoform Activity of Phosphoinositide 3-Kinase Inhibits Blast Cell Proliferation in Acute Myeloblastic Leukemia.

Blood (2004) 104 (11): 2522.

https://doi.org/10.1182/blood.V104.11.2522.2522

Published: 2004

Journal Articles

Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Societe Francaise de Greffe de Moelle

Blood (1996) 88 (1): 358–365.

https://doi.org/10.1182/blood.V88.1.358.358

Published: 1996

Journal Articles

STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients

V Gouilleux-Gruart, F Gouilleux, C Desaint, JF Claisse, JC Capiod, J Delobel, R Weber-Nordt, I Dusanter-Fourt, F Dreyfus, B Groner, L Prin

Blood (1996) 87 (5): 1692–1697.

https://doi.org/10.1182/blood.V87.5.1692.1692

Published: 1996

Journal Articles

High-dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: results of a phase II trial involving 63 patients

JP Fermand, S Chevret, P Ravaud, M Divine, V Leblond, F Dreyfus, X Mariette, JC Brouet

Blood (1993) 82 (7): 2005–2009.

https://doi.org/10.1182/blood.V82.7.2005.2005

Published: 1993

Journal Articles

Expression of the c-mpl proto-oncogene in human hematologic malignancies

I Vigon, F Dreyfus, J Melle, F Viguie, V Ribrag, L Cocault, M Souyri, S Gisselbrecht

Blood (1993) 82 (3): 877–883.

https://doi.org/10.1182/blood.V82.3.877.877

Published: 1993

Journal Articles

Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia

E Archimbaud, V Leblond, M Michallet, C Cordonnier, P Fenaux, P Travade, F Dreyfus, J Jaubert, Y Devaux, D Fiere

Blood (1991) 77 (9): 1894–1900.

https://doi.org/10.1182/blood.V77.9.1894.1894

Published: 1991

NARROW

MDS with Isolated Neutropenia or Thrombocytopenia. Incidence and Characteristics in the Groupe Francophone des Myélodysplasies (GFM) Registry.

Bortezomib + Low Dose Cytarabine in Int-2 and High Risk MDS. Interim Results of a Phase I/II Trial by the GFM.

Lenalidomide (LEN) in INT 2 and High Risk MDS with DEL 5q. Interim Results of a Phase II Trial by the GFM.

Prognostic Factors and Response Duration in 419 MDS Treated with Erythropoietin±GCSF: The GFM Experience.

RBC Transfusions and Iron Chelation Therapy in Clinical Practice in MDS: A One Month Survey by the GFM.

Low Doses of Thalidomide (Thal) in Low Risk MDS with Transfusion-Dependant Anemia: The GFM THAL-SMD-200 Trial.

Is There a Role for ATRA in Combination to EPO in Lower Risk Myelodysplastic Syndrome? Preliminary Results of a Phase II Study.

Thalidomide for the Treatment of Low Risk Myelodysplasia.

High Response Rate to Darbopoetin Alfa in “Low Risk” MDS : Results of a Phase II Study.

Blockade of p110delta Isoform Activity of Phosphoinositide 3-Kinase Inhibits Blast Cell Proliferation in Acute Myeloblastic Leukemia.

Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Societe Francaise de Greffe de Moelle

STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients

High-dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: results of a phase II trial involving 63 patients

Expression of the c-mpl proto-oncogene in human hematologic malignancies

Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only